Literature DB >> 17540729

Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization.

Peng Fei Zhang1, Fatim Cham, Ming Dong, Anil Choudhary, Peter Bouma, Zhiqiang Zhang, Yiming Shao, Yan-Ru Feng, Lemin Wang, Nathalie Mathy, Gerald Voss, Christopher C Broder, Gerald V Quinnan.   

Abstract

An immunization regimen was evaluated in rabbits consisting of the soluble, oligomeric form of envelope glycoprotein of HIV-1, strain R2 (gp140(R2)), or the surface component of the same envelope (Env), gp120(R2), in the adjuvant AS02A. The gp140(R2) was selected based on its unusual CD4-independent phenotype and the exceptionally broad neutralizing response in the infected donor. The gp140(R2) immunogen induced antibodies that achieved 50% neutralization of 48/48, and 80% neutralization of 43/46 primary strains of diverse HIV-1 subtypes tested. The strains tested included members of standard panels of subtype B and C strains, and other diverse strains known to be neutralization resistant. The gp120(R2) induced antibodies that neutralized 9/48 of the same strains. Neutralization was IgG-mediated and HIV-1-specific. These results demonstrate that induction of truly broad spectrum neutralizing antibodies is an achievable goal in HIV-1 vaccine development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17540729      PMCID: PMC1885220          DOI: 10.1073/pnas.0608635104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

Review 1.  Antibodies, viruses and vaccines.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

2.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

3.  A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.

Authors:  Peng Fei Zhang; Peter Bouma; Eun Ju Park; Joseph B Margolick; James E Robinson; Susan Zolla-Pazner; Michael N Flora; Gerald V Quinnan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity.

Authors:  Mark K Louder; Anna Sambor; Elena Chertova; Tai Hunte; Sarah Barrett; Fallon Ojong; Eric Sanders-Buell; Susan Zolla-Pazner; Francine E McCutchan; James D Roser; Dana Gabuzda; Jeffrey D Lifson; John R Mascola
Journal:  Virology       Date:  2005-09-01       Impact factor: 3.616

5.  Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus.

Authors:  T Igarashi; Y Endo; G Englund; R Sadjadpour; T Matano; C Buckler; A Buckler-White; R Plishka; T Theodore; R Shibata; M Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

6.  Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system.

Authors:  Ming Dong; Peng Fei Zhang; Franziska Grieder; James Lee; Govindaraj Krishnamurthy; Thomas VanCott; Christopher Broder; Victoria R Polonis; Xiao-Fang Yu; Yiming Shao; Dennis Faix; Patricia Valente; Gerald V Quinnan
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine.

Authors:  Gerald Voss; Kelledy Manson; David Montefiori; David I Watkins; Jonathan Heeney; Michael Wyand; Joe Cohen; Claudine Bruck
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  49 in total

1.  Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies.

Authors:  Gilad Kaplan; Anna Roitburd-Berman; George K Lewis; Jonathan M Gershoni
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

2.  Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.

Authors:  Jennifer L Kirchherr; Jennifer Hamilton; Xiaozhi Lu; S Gnanakaran; Mark Muldoon; Marcus Daniels; Webster Kasongo; Victor Chalwe; Chanda Mulenga; Lawrence Mwananyanda; Rosemary M Musonda; Xing Yuan; David C Montefiori; Bette T Korber; Barton F Haynes; Feng Gao
Journal:  Virology       Date:  2010-10-30       Impact factor: 3.616

Review 3.  Role of adjuvants in modeling the immune response.

Authors:  Darrick Carter; Steven G Reed
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

4.  Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Authors:  Zane Kraft; Katharine Strouss; William F Sutton; Brad Cleveland; For Yue Tso; Patricia Polacino; Julie Overbaugh; Shiu-Lok Hu; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

5.  Immune distribution and localization of phosphoantigen-specific Vgamma2Vdelta2 T cells in lymphoid and nonlymphoid tissues in Mycobacterium tuberculosis infection.

Authors:  Dan Huang; Yun Shen; Liyou Qiu; Crystal Y Chen; Ling Shen; Jim Estep; Robert Hunt; Daphne Vasconcelos; George Du; Pyone Aye; Andrew A Lackner; Michelle H Larsen; William R Jacobs; Barton F Haynes; Norman L Letvin; Zheng W Chen
Journal:  Infect Immun       Date:  2007-10-08       Impact factor: 3.441

6.  Probing the HIV gp120 envelope glycoprotein conformation by NMR.

Authors:  Jessica Celigoy; Benjamin Ramirez; Lin Tao; Lijun Rong; Lianying Yan; Yan-Ru Feng; Gerald V Quinnan; Christopher C Broder; Michael Caffrey
Journal:  J Biol Chem       Date:  2011-05-18       Impact factor: 5.157

7.  Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Authors:  Catherine A Blish; D Noah Sather; George Sellhorn; Leonidas Stamatatos; Yide Sun; Indresh Srivastava; Susan W Barnett; Brad Cleveland; Julie Overbaugh; Shiu-lok Hu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

8.  Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.

Authors:  Yun Li; Bradley Cleveland; Igor Klots; Bruce Travis; Barbra A Richardson; David Anderson; David Montefiori; Patricia Polacino; Shiu-Lok Hu
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

9.  HIV-1 neutralization by monoclonal antibody against conserved region 2 and patterns of epitope exposure on the surface of native viruses.

Authors:  Apichai Sreepian; Jongruk Permmongkol; Wannee Kantakamalakul; Sontana Siritantikorn; Nattaya Tanlieng; Ruengpung Sutthent
Journal:  J Immune Based Ther Vaccines       Date:  2009-10-12

10.  Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.

Authors:  Tessa Dieltjens; Leo Heyndrickx; Betty Willems; Elin Gray; Lies Van Nieuwenhove; Katrijn Grupping; Guido Vanham; Wouter Janssens
Journal:  Retrovirology       Date:  2009-12-14       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.